About Us – CYTEA BIO

4+

(POTENTIAL PRODUCT CANDIDATES)

(COMPANY)

ABOUT CYTEA|BIO

A UNIQUELY VERSATILE PLATFORM TO ADDRESS COMPLEX AND CHALLENGING PATHOLOGIES

6+

(YEARS OF ACADEMIC RESEARCH BEHIND THE PLATFORM)

CYTEA|BIO IS A PRECLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSING ON ALLOGENEIC CELLULAR IMMUNOTHERAPIES. THE COMPANY HAS DEVELOPED AND PATENTED A VERSATILE AND MODULAR CELL THERAPY PLATFORM (PIN™ PLATFORM).

THE PLATFORM SOLVES THE PROBLEM OF PRE-ARMING NORMAL POTENT EFFECTOR CELLS WITHOUT CELL MODIFICATION THEREFORE PROVIDING THE OPPORTUNITY TO CREATE MULTIPLE THERAPEUTIC PRODUCTS AND COMBINATIONS FROM WELL-UNDERSTOOD COMPONENTS.

∞

(POTENTIAL COMBINATIONS)

MORE ABOUT OUR TECHNOLOGY

(CONCEPT)

OUR PIN PLATFORM

(CD 16 RECEPTORS)

NATURAL EFFECTOR CELLS

ANY EFFECTOR CELL HAVING A NATURAL OR INDUCED CD16 RECEPTOR ON ITS SURFACE CAN BE USED WITHIN THE PLATFORM, INCLUDING NK CELLS OR MACROPHAGES.

+

(PRE-ARMING)

TARGETING LIGANDS

ANY SINGLE OR MULTIPLE MONOCLONAL ANTIBODIES, OR OTHER FC-BASED LIGANDS CAN BE USED, ONCE ENGINEERED, TO PRE-ARM THE EFFECTOR CELLS BEFORE THERAPEUTIC INJECTIONS

=

(HARNESSING)

DRUG PRODUCT

THE PLATFORM BRINGS TOGETHER POTENT HUMAN CELLS AND TARGETING LIGANDS, HARNESSING NATURAL IMMUNE PROCESSES BASED ON CONVENTIONAL MOLECULAR RECOGNITION, NORMAL CELL SIGNALLING AND EFFECTOR FUNCTION.

(DEVELOPMENT)

PIPELINE

LEAD PROGRAM IN GLIOBLASTOMA

(POTENCY)

STRONG CYTOTOXICTY

PRE-CLINICAL DATA DEMONSTRATES STRONG CYTOTOXICITY AGAINST A NUMBER OF TARGETED CELLS, INCLUDING HUMAN CANCER CELLS.

(PERSISTENCE)

STRONG ARMING

PRE-ARMING OF EFFECTOR CELLS NOT PRACTICAL WITHOUT CYTEA BIO’S PATENTED TECHNOLOGY. TRANSFORMS ABILITY OF THERAPEUTIC CELLS TO FIND AND ENGAGE TARGET. DRAMATICALLY SUPERIOR LOADING AND PERSISTENCE OF TARGETING LIGANDS.

(VERSATILITY)

MODULAR APPROACH

FUTURE GENERATIONS OF PRODUCTS INCLUDE MULTIPLE ARMED CELLS PROVIDING INCREASED SPECIFICITY, MIXED CELL POPULATIONS TO BRING TOGETHER SIMULTANEOUS EFFECTOR FUNCTIONS FOR INCREASED POTENCY. ECONOMICS OF THE PLATFORM ARE LIKELY TO BE SIGNIFICANTLY MORE EFFICIENT THAN CELL MODIFICATION APPROACHES SUCH AS CAR.

(TEAM)

TEAM

EXPERIENCED SENIOR EXECUTIVES

ALAN COOKSON, PHD

CEO

Over 40 years of experience in the pharmaceutical and healthcare industry. Founder of several biotechnology start-ups.

LIONEL BRODARD

CFO

Manager with experience in start-ups and biotech (Celgene). HEC, HSG & EPFL training.

MARC CRITON, PHD, MBA

COO

Manager with over 26 years of experience in pharmaceutical industry. IP and Business Development oriented.

BENEDICTE FAUVEL, PHD

VP, HEAD OF PRE-CLINICAL DEVELOPMENT

JESSY PRESUMEY, PHD

VP, HEAD OF SCIENCE

SUPPORTED BY A WORLD CLASS INTERNATIONAL BOARD OF DIRECTORS

LAURENT ZBINDEN

FOUNDER, INVESTOR & VICE-CHAIRMAN

Serial entrepreneur and former. CEO of multiple companies with more than 30 years experience.

JOHN D. MCMANNIS, PHD

BOARD MEMBER

Former Head of Manufacturing at Mesoblast (NASDAQ: MESO). Ex- Professor at UTMD Anderson Cancer Center. Led the Cell Therapy Laboratory at UTMD and designed its facility.

ANH NGUYEN, PHD

INVESTOR & EXECUTIVE CHAIRMAN

Co-founder and Chairman of MedinCell (EPA:MEDCL). Co- founder of Syntro (NASDAQ 1987) and Invitrogen (NASDAQ 1999). Invitrogen was acquired by Thermo Fisher in 2013 for $16bn.

ANDREW GALAZKA, M.D.

BOARD MEMBER

Former SVP Global Clinical Development at Merck KGaA with a strong track record of drug approval (Rebif, Mavenclad). Previously Head of Scientific Affairs and Investor Relations at Serono (listing NYSE).

GABRIEL BAERTSCHI

BOARD MEMBER

CEO of the Grünenthal Group (€ 1,4B Sales, 4’700 employees in 2019). Previously Company President of AstraZeneca Japan and Germany. Managed brands in immuno-oncology.

J.-J. DE DARDEL, PHD

BOARD MEMBER

Non-executive director. Formerly Ambassador to The People’s Republic of China, to Mongolia and the DPRK (2014-2019). Previously Ambassador to France and Monaco (2011-2014).

WORLD CLASS GBM CLINICAL & SCIENTIFIC ADVISORY BOARD

ROGER STUPP

NEURO-ONCOLOGIST

Internationally renowned medical oncologist and neuro-oncologist (Northwestern University). Best known for his contributions in the first line treatment protocol of brain tumors (the “Stupp protocol”)